CN115916162A - 用于冠状病毒治疗的吡非尼酮 - Google Patents

用于冠状病毒治疗的吡非尼酮 Download PDF

Info

Publication number
CN115916162A
CN115916162A CN202180042472.1A CN202180042472A CN115916162A CN 115916162 A CN115916162 A CN 115916162A CN 202180042472 A CN202180042472 A CN 202180042472A CN 115916162 A CN115916162 A CN 115916162A
Authority
CN
China
Prior art keywords
pirfenidone
subject
cov
sars
coronavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180042472.1A
Other languages
English (en)
Chinese (zh)
Inventor
E.阿吉拉-科多瓦
L.阿吉拉
J.A.R.马加纳卡斯特罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exkaliber Pharmaceutical Co ltd
Original Assignee
Exkaliber Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exkaliber Pharmaceutical Co ltd filed Critical Exkaliber Pharmaceutical Co ltd
Publication of CN115916162A publication Critical patent/CN115916162A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
CN202180042472.1A 2020-04-14 2021-04-14 用于冠状病毒治疗的吡非尼酮 Pending CN115916162A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063010009P 2020-04-14 2020-04-14
US63/010,009 2020-04-14
PCT/US2021/027335 WO2021211745A1 (en) 2020-04-14 2021-04-14 Pirfenidone for coronavirus treatment

Publications (1)

Publication Number Publication Date
CN115916162A true CN115916162A (zh) 2023-04-04

Family

ID=78084909

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180042472.1A Pending CN115916162A (zh) 2020-04-14 2021-04-14 用于冠状病毒治疗的吡非尼酮

Country Status (14)

Country Link
US (1) US20230117397A1 (enExample)
EP (1) EP4135671A4 (enExample)
JP (1) JP2023521887A (enExample)
KR (1) KR20230038644A (enExample)
CN (1) CN115916162A (enExample)
AU (1) AU2021254765A1 (enExample)
BR (1) BR112022020821A2 (enExample)
CA (1) CA3175526A1 (enExample)
CL (1) CL2022002843A1 (enExample)
CO (1) CO2022016155A2 (enExample)
EC (1) ECSP22087664A (enExample)
IL (1) IL297296A (enExample)
MX (1) MX2022012986A (enExample)
WO (1) WO2021211745A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117503721A (zh) * 2022-04-29 2024-02-06 越洋医药开发(广州)有限公司 一种吡非尼酮持续性释放口服固体制剂

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
CN114796122B (zh) * 2022-03-30 2023-03-24 山东大学 一种聚多巴胺载吡菲尼酮纳米粒及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU709178B2 (en) * 1995-09-19 1999-08-26 Intermune, Inc. Inhibition of tumor necrosis factor alpha
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
WO2003030720A2 (en) * 2001-10-09 2003-04-17 The Children's Hospital Of Philadelphia Materials and methods for preventing or reducing scar formation
US20070072181A1 (en) * 2003-02-28 2007-03-29 Blatt Lawrence M Combination therapy for treating alphavirus infection and liver fibrosis
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
MX2007014114A (es) * 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
CN101088557A (zh) * 2006-06-12 2007-12-19 天津市扶素生物技术有限公司 用于预防或治疗hiv感染的药用组合物及其应用
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
SG176053A1 (en) * 2009-05-15 2011-12-29 Intermune Inc Methods of treating hiv patients with anti-fibrotics
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
ES2913095T3 (es) * 2011-01-31 2022-05-31 Avalyn Pharma Inc Compuestos de pirfenidona y análogos de piridona en aerosol y usos de los mismos
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
WO2013181691A1 (en) * 2012-06-04 2013-12-12 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd A method of treatment and compositions useful therefor, screening and prognostic agents and uses therefor
EP4491180A1 (en) * 2014-01-10 2025-01-15 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117503721A (zh) * 2022-04-29 2024-02-06 越洋医药开发(广州)有限公司 一种吡非尼酮持续性释放口服固体制剂

Also Published As

Publication number Publication date
CA3175526A1 (en) 2021-10-21
US20230117397A1 (en) 2023-04-20
EP4135671A1 (en) 2023-02-22
IL297296A (en) 2022-12-01
EP4135671A4 (en) 2024-08-14
WO2021211745A1 (en) 2021-10-21
BR112022020821A2 (pt) 2022-12-20
CL2022002843A1 (es) 2023-09-01
MX2022012986A (es) 2023-03-21
ECSP22087664A (es) 2022-12-30
AU2021254765A1 (en) 2022-12-08
KR20230038644A (ko) 2023-03-21
JP2023521887A (ja) 2023-05-25
CO2022016155A2 (es) 2022-12-20

Similar Documents

Publication Publication Date Title
US20230117397A1 (en) Pirfenidone for coronavirus treatment
EP2799071B1 (en) Levocetirizine and montelukast for the treatment of influenza and common cold
AU2019328903B2 (en) Composition for eradicating Helicobacter pylori
JP2007291067A (ja) 医薬組成物
KR102766876B1 (ko) 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 코로나바이러스감염증-19(covid-19) 치료용 조성물
JP2023521887A5 (enExample)
US20210236580A1 (en) Methods and Compositions for Mitigating Symptoms of Acute Respiratory Distress Syndrome
CN113633649A (zh) 瑞德西韦及其核苷的组合制剂在抗猪流行性腹泻病毒中的应用
EP4613275A1 (en) Pharmaceutical use of nucleoside compound
JP2010083871A (ja) 抗アデノウイルス剤を含有する医薬組成物
JP4829478B2 (ja) 医薬組成物
Ng et al. Use of montelukast in the treatment of early childhood wheezing from clinical experience with three cases
CN112220783A (zh) 一种西那卡塞通过nk1r靶点治疗炎性肠病的医药用途
US20250339442A1 (en) Methods of treatment using a dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) inhibitor
JP2004331660A (ja) 医薬組成物
JP4444721B2 (ja) 医薬組成物
JP2024512051A (ja) ウイルス感染症を処置するためのメベンダゾールの使用
TW202615028A (zh) 錠劑配方
JP5128532B2 (ja) 医薬組成物
US20230310467A1 (en) PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + REMDESIVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDI COVID-19
CN120302974A (zh) 喹诺林化合物治疗甲状腺癌的用途
TW202143985A (zh) 治療之方法
HK1199815B (en) Levocetirizine and montelukast for the treatment of influenza and common cold
JP2009143966A (ja) 医薬組成物
JP2010106012A (ja) 抗アデノウイルス剤及びそれを含有する医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination